We are live on
!
Find out more
Alyeska Investment Group Portfolio holdings
AUM
$35.4B
1-Year Est. Return
33.54%
This Fund
S&P 500
This Quarter
Est. Return
+3.53%
1 Year Est. Return
+33.54%
3 Year Est. Return
+101.08%
5 Year Est. Return
+102.29%
10 Year Est. Return
+544.32%
AUM
$12B
AUM Growth
-$353M
(-2.9%)
Cap. Flow
-$617M
Cap. Flow
% of AUM
-5.16%
Top 10 Holdings %
Top 10 Hldgs %
12.46%
Holding
637
New
171
Increased
105
Reduced
150
Closed
191
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Delta Air Lines
DAL
|
+$140M |
| 2 |
AbbVie
ABBV
|
+$119M |
| 3 |
KeyCorp
KEY
|
+$115M |
| 4 |
F5
FFIV
|
+$111M |
| 5 |
Walmart Inc
WMT
|
+$110M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oracle
ORCL
|
+$146M |
| 2 |
S&P Global
SPGI
|
+$142M |
| 3 |
Eli Lilly
LLY
|
+$133M |
| 4 |
Labcorp
LH
|
+$131M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$121M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.86% |
| 2 | Healthcare | 13.19% |
| 3 | Industrials | 12.91% |
| 4 | Consumer Discretionary | 10.27% |
| 5 | Financials | 9.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
351
Invesco
IVZ
$14.3B
| $2M | 0.02% |
+56,919
| New | +$1.86M |
|
|
MGI
352
DELISTED
MoneyGram International, Inc. New
MGI
| $1.99M | 0.02% |
+115,349
| New | +$1.99M |
|
353
Manchester United
MANU
$3.84B
| $1.92M | 0.02% |
118,389
-145,598
| -55% | -$2.41M |
|
|
QTNT
354
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $1.88M | 0.02% |
6,368
-8,730
| -58% | -$2.46M |
|
|
ESRX
355
DELISTED
Express Scripts Holding Company
ESRX
| $1.86M | 0.02% |
+29,072
| New | +$1.83M |
|
356
Wave Life Sciences
WVE
$1.19B
| $1.84M | 0.02% |
+98,801
| New | +$2.13M |
|
|
CFRX
357
CALL
DELISTED
ContraFect Corporation
CFRX
| $1.81M | 0.02% |
1,563
| – | – |
|
358
Akebia Therapeutics
AKBA
$252M
| $1.8M | 0.02% |
+125,000
| New | +$1.58M |
|
|
MRSN
359
DELISTED
Mersana Therapeutics
MRSN
| $1.75M | 0.01% |
+5,000
| New | +$1.73M |
|
360
ITT
ITT
$20.3B
| $1.75M | 0.01% |
43,424
-459,131
| -91% | -$18.3M |
|
361
Boeing
BA
$187B
| $1.71M | 0.01% |
+8,636
| New | +$1.61M |
|
|
OMED
362
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $1.71M | 0.01% |
512,563
-193,677
| -27% | -$804K |
|
|
AZUL
363
DELISTED
Azul
AZUL
| $1.7M | 0.01% |
+80,601
| New | +$1.8M |
|
|
EXA
364
DELISTED
EXA Corporation
EXA
| $1.67M | 0.01% |
+120,745
| New | +$1.62M |
|
|
CXO
365
DELISTED
CONCHO RESOURCES INC.
CXO
| $1.62M | 0.01% |
+13,348
| New | +$1.69M |
|
|
LSI
366
DELISTED
Life Storage, Inc.
LSI
| $1.62M | 0.01% |
32,789
-996
| -3% | -$51.7K |
|
|
FCE.A
367
DELISTED
Forest City Realty Trust, Inc.
FCE.A
| $1.57M | 0.01% |
65,011
+4,774
| +8% | +$110K |
|
368
Morgan Stanley
MS
$341B
| $1.56M | 0.01% |
+34,982
| New | +$1.51M |
|
|
CTIC
369
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
| $1.54M | 0.01% |
+466,529
| New | +$1.82M |
|
370
DigitalBridge
DBRG
$2.95B
| $1.5M | 0.01% |
26,617
-26,640
| -50% | -$1.45M |
|
371
Hubbell
HUBB
$27.2B
| $1.47M | 0.01% |
+12,988
| New | +$1.5M |
|
372
Kimco Realty
KIM
$16.6B
| $1.45M | 0.01% |
+79,153
| New | +$1.55M |
|
|
PTN
373
Palatin Technologies
PTN
$14.3M
| $1.43M | 0.01% |
2,660
-80
| -3% | -$38.3K |
|
374
Zymeworks
ZYME
$1.72B
| $1.43M | 0.01% |
+170,821
| New | +$1.91M |
|
375
Devon Energy
DVN
$49.5B
| $1.39M | 0.01% |
43,530
-65,949
| -60% | -$2.41M |
|
Similar funds
SAM
VIA
Alyeska Investment Group's Q2 2017 Portfolio in Review
As of Q2 2017, Alyeska Investment Group held 637 positions worth $12B, down 2.9% from $12.3B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Alyeska Investment Group withdrew a net $617M in Q2 2017, closing 191 positions and reducing 150 holdings. Its most notable exit was Eli Lilly, an estimated $133M position sold in full.
By sector, the portfolio is most concentrated in Technology at 18% of assets, up from 14% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Alyeska Investment Group opened a new position in AbbVie worth $128M.
- Alyeska Investment Group's largest Q2 2017 buy was AbbVie: 1,771,895 shares worth $128M.
- Alyeska Investment Group added most to Delta Air Lines in Q2 2017, an estimated $140M increase.
- Alyeska Investment Group's biggest Q2 2017 reduction was Oracle, cutting an estimated $146M.
- Alyeska Investment Group fully exited Eli Lilly in Q2 2017, selling an estimated $133M.
- Alyeska Investment Group's ten largest holdings make up 12% of its $12B portfolio in Q2 2017.
- Alyeska Investment Group opened 171 new positions and closed 191 in Q2 2017.
- Alyeska Investment Group's portfolio value fell 2.9% quarter-over-quarter to $12B.
Based on Alyeska Investment Group's 13F filing for Q2 2017, filed 14 Aug 2017.